首页|The Outcomes of Ponatinib Therapy in Patients With Chronic Myeloid Leukemia Resistant or Intolerant to Previous Tyrosine Kinase Inhibitors , Treated in Poland Within the Donation Program

The Outcomes of Ponatinib Therapy in Patients With Chronic Myeloid Leukemia Resistant or Intolerant to Previous Tyrosine Kinase Inhibitors , Treated in Poland Within the Donation Program

扫码查看
原文链接
  • NSTL
  • Cig Media Group, Lp
Ponatinib is a new pan-inhibitor of tyrosine kinase active in resistant chronic myeloid leukemia (CML). Evaluation of outcomes in 43 patients confirmed ponatinib efficacy in a significant proportion of subjects heavily pre-treated with tyrosine kinase inhibitors achieving durable responses in both chronic phase and accelerated/blastic phase CML groups. Introduction: Tyrosine kinase inhibitors (TKIs) have greatly improved the treatment outcome for most patients with chronic myeloid leukemia (CML). Ponatinib is a new pan-inhibitor of TK active in resistant CML. This study aimed to evaluate the efficacy and safety of ponatinib in patients suffering from CML. Patients and methods: This multicenter, non-randomized, observational, retrospective study evaluated the efficacy and safety of ponatinib administered in adult CML patients in any disease phase, including those with a detected ABL T315I mutation, which were resistant or intolerant to previous-generation TKIs. The study comprised 43 patients benefiting from the ponatinib donation program who were treated in 16 Polish centers. Results: For patients who started treatment with ponatinib in chronic phase (CP) (n = 23) and in accelerated phase (AP) (n = 3) the median time on ponatinib was 19.5 months (range: 1.0-35.4), and 31.7 months (range: 31.0-34.1), respectively. All these patients were in CP after 1 month of treatment and at the end of observation - none of them progressed to AP or blastic phase (BP) during the study, meaning that progression-free survival was 100% at the end of observation (35.4 months). The estimated 2-year survival in this group of patients was 84%. For all 43 patients, median survival was not reached (lower quartile 6.3 months), and estimated 2-year survival was 60%. Conclusion: Our analysis confirmed ponatinib efficacy in a significant proportion of patients heavily pre-treated with TKIs achieving durable responses in both CP and AP/BP CML groups.

Third generation TKIreal-life dataefficacy and safetyresistanceintoleranceCMLCHRONIC MYELOGENOUS LEUKEMIAIMATINIB RESISTANCEFOLLOW-UPCMLRECOMMENDATIONSTRANSCRIPTSURVIVALINTERFERONMANAGEMENTMUTATIONS

Sacha, Tomasz、Szczepanek, Elzbieta、Dumnicka, Paulina、Gora-Tybor, Joanna、Niesiobedzka-Krezel, Joanna、Prejzner, Witold、Wasilewska, Ewa、Kloczko, Janusz、Ciepluch, Hanna、Makowska, Wioletta、Patkowska, Elzbieta、Wasilewska, Joanna、Bober, Grazyna、Kopera, Malgorzata、Wichary, Ryszard、Kroll-Balcerzak, Renata、Gromek, Tomasz、Wach, Malgorzata、Rudkowska-Kazanowska, Anna、Swiniarska, Magdalena、Paczkowska, Edyta、Biernat, Monika、Joks, Monika、Oller, Marta、Kasza, Renata、Kostyra, Aleksandra、Gil, Justyna、Grzybowska-Izydorczyk, Olga

展开 >

Dept Hematol,Jagiellonian Univ Med Coll

Fac Pharm,Jagiellonian Univ Med Coll

Copernicus Mem Hosp,Med Univ Lodz

Dept Hematol Transplantat & Internal Med,Med Univ Warsaw

Dept Hematol & Transplantol,Med Univ Gdansk

Dept Hematol,Med Univ Bialystok

Dept Hematol,Copernicus Reg Oncol Ctr

Dept Hematol,Inst Hematol & Transfus Med

Sch Med Katowice,Med Univ Silesia

Dept Hematol & Bone Marrow Transplantat,Poznan Univ Med Sci

Dept Hematooncol & Bone Marrow Transplantat,Med Univ Lublin

Sch Publ Hlth Bytom,Med Univ Silesia

Dept Hematol & Transplantol,Pomeranian Med Univ

Dept Gen Pathol,Pomeranian Med Univ

Dept Hematol Blood Neoplasms & Bone Marrow Transp,Wroclaw Med Univ

Dept Hematol,Zamosc Hosp

Dept Hematol,Prov Hosp

Dept Hematooncol,Oncol Ctr Podkarpackie Prov

展开 >

2022

10.1016/j.clml.2021.11.012

Clinical lymphoma, myeloma & leukemia

Clinical lymphoma, myeloma & leukemia

ISSN：2152-2650
年,卷(期)：2022.22(6)
  • 49